ES2194567B1 - Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas. - Google Patents

Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas.

Info

Publication number
ES2194567B1
ES2194567B1 ES200050033A ES200050033A ES2194567B1 ES 2194567 B1 ES2194567 B1 ES 2194567B1 ES 200050033 A ES200050033 A ES 200050033A ES 200050033 A ES200050033 A ES 200050033A ES 2194567 B1 ES2194567 B1 ES 2194567B1
Authority
ES
Spain
Prior art keywords
phenyl
imidazotriazinonas
fenil
replaced
phosphodiesterase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200050033A
Other languages
English (en)
Other versions
ES2194567A1 (es
Inventor
Ulrich Niewohner
Mazen Es-Sayed
Helmut Haning
Thomas Schenke
Karl-Heinz Schlemmer
Jorg Keldenich
Erwin Bischoff
Elisabeth Perzborn
Klaus Dembowsky
Peter Serno
Marc Nowakowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2194567(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/de
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/de
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/de
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of ES2194567A1 publication Critical patent/ES2194567A1/es
Application granted granted Critical
Publication of ES2194567B1 publication Critical patent/ES2194567B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a imidazotriazinonas 2-fenil sustituidas con radicales alquilo cortos no ramificados en posición 9 de acuerdo con la fórmula general (I). Dichas imidazotriazinonas 2-fenil sustituidas se producen de las correspondientes 2-fenil imidazotriaziononas por clorosulfonación y la reacción subsiguiente con las aminas. Estos compuestos inhiben las fosfodiesterasas que metabolizan GMPc y son adecuadas para su uso como los agentes activos en los medicamentos para tratar las enfermedades cardiovasculares y cerebrovasculares y/o enfermedades del sistema urogenital, especialmente para el tratamiento de la disfunción erectil.
ES200050033A 1997-11-12 1998-10-31 Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas. Expired - Fee Related ES2194567B1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19750085 1997-11-12
DE19750085A DE19750085A1 (de) 1997-11-12 1997-11-12 2-Phenyl-substituierte Imidazotriazinone
DE19812462 1998-03-23
DE1998112462 DE19812462A1 (de) 1998-03-23 1998-03-23 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
DE19840289 1998-09-04
DE1998140289 DE19840289A1 (de) 1998-09-04 1998-09-04 2-Phenyl-substituierte Imidazotriazinone

Publications (2)

Publication Number Publication Date
ES2194567A1 ES2194567A1 (es) 2003-11-16
ES2194567B1 true ES2194567B1 (es) 2005-03-01

Family

ID=27217917

Family Applications (3)

Application Number Title Priority Date Filing Date
ES01123321T Expired - Lifetime ES2386420T3 (es) 1997-11-12 1998-10-31 Imidazotriazinonas sustituidas con fenilo en la posición 2 como inhibidores de fosfodiesterasas
ES98959821T Expired - Lifetime ES2172945T3 (es) 1997-11-12 1998-10-31 Imidazotriazinonas sustituidas en 2 con fenilo como inhibidores de fosfodiesterasas.
ES200050033A Expired - Fee Related ES2194567B1 (es) 1997-11-12 1998-10-31 Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES01123321T Expired - Lifetime ES2386420T3 (es) 1997-11-12 1998-10-31 Imidazotriazinonas sustituidas con fenilo en la posición 2 como inhibidores de fosfodiesterasas
ES98959821T Expired - Lifetime ES2172945T3 (es) 1997-11-12 1998-10-31 Imidazotriazinonas sustituidas en 2 con fenilo como inhibidores de fosfodiesterasas.

Country Status (44)

Country Link
US (9) US6362178B1 (es)
EP (3) EP2295436A1 (es)
JP (2) JP3356428B2 (es)
KR (2) KR100430355B1 (es)
CN (2) CN100430396C (es)
AR (2) AR013759A1 (es)
AT (1) ATE213246T1 (es)
AU (1) AU738675B2 (es)
BG (1) BG65257B1 (es)
BR (2) BR9812785A (es)
CA (2) CA2395558C (es)
CH (1) CH693954A5 (es)
CO (1) CO4980861A1 (es)
CU (1) CU23063A3 (es)
CY (1) CY1112949T1 (es)
CZ (1) CZ301911B6 (es)
DE (3) DE59803108D1 (es)
DK (3) DK1174431T3 (es)
EE (1) EE04781B1 (es)
ES (3) ES2386420T3 (es)
FI (1) FI113772B (es)
GB (1) GB2346877B (es)
HK (2) HK1031730A1 (es)
HN (1) HN1998000175A (es)
HR (2) HRP20000292B1 (es)
HU (3) HU227841B1 (es)
ID (1) ID25871A (es)
IL (3) IL135462A0 (es)
IN (1) IN188419B (es)
LU (1) LU90561B1 (es)
MY (1) MY138535A (es)
NO (2) NO314940B1 (es)
NZ (1) NZ504436A (es)
PE (1) PE131799A1 (es)
PL (2) PL194801B1 (es)
PT (2) PT1049695E (es)
SE (1) SE522809C2 (es)
SI (2) SI1174431T1 (es)
SK (1) SK287161B6 (es)
TR (1) TR200001338T2 (es)
TW (2) TWI229081B (es)
UA (1) UA46166C2 (es)
UY (2) UY25246A1 (es)
WO (1) WO1999024433A1 (es)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
EP2295436A1 (de) * 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
IL139454A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
AU2841801A (en) 1999-12-24 2001-07-09 Bayer Aktiengesellschaft Triazolotriazinones and the use thereof
KR20020062770A (ko) 1999-12-24 2002-07-29 바이엘 악티엔게젤샤프트 이미다조 1,3,5 트리아지논 및 그의 용도
EP1252165A1 (de) 1999-12-24 2002-10-30 Bayer Aktiengesellschaft Isoxazolopyrimidinone und ihre verwendung
DE10010067A1 (de) 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
CN1436080A (zh) 2000-04-19 2003-08-13 利利艾科斯有限公司 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AU2001290146A1 (en) * 2000-09-29 2002-04-08 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
DE10063106A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
CA2449163C (en) * 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
GB0113344D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE60226615D1 (es) 2001-08-28 2008-06-26 Schering Corp
WO2003042216A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
EP1454897B1 (en) * 2001-12-13 2007-10-10 Asubio Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003265239A1 (en) 2002-05-22 2003-12-19 Virginia Commonwealth University Protective effects of pde-5 inhibitors
CN1655820A (zh) * 2002-05-23 2005-08-17 辉瑞大药厂 Pde5抑制剂与ace抑制剂的药物组合
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
ES2326808T3 (es) * 2003-04-01 2009-10-20 Smithkline Beecham Corporation Compuestos de imidazotriazina para el tratamiento de enfermedades cancerosas.
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
NZ544040A (en) 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
EP1708718A1 (en) 2004-01-22 2006-10-11 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
DE602005011784D1 (de) * 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
JP2008501617A (ja) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
CA2598270A1 (en) * 2005-02-18 2006-08-24 Surface Logix, Inc. Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
JP2008530247A (ja) * 2005-02-18 2008-08-07 サーフェイス ロジックス，インコーポレイティド 薬物動態学的に改善された化合物
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DK2366393T3 (da) 2005-04-19 2013-10-21 Takeda Gmbh Roflumilast til behandlingen af pulmonal hypertension
US8227475B2 (en) 2005-05-12 2012-07-24 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006127368A2 (en) * 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2637615A1 (en) * 2006-02-17 2007-08-30 Wyeth Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
RU2448087C2 (ru) * 2006-03-17 2012-04-20 Джонс Хопкинс Юниверсити Скул Оф Медсин Производные n-гидроксилсульфонамида в качестве новых физиологически полезных доноров нитроксила
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
CA2655061A1 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
JP2010501577A (ja) * 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド 薬物動態が改善された化合物
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
AU2007333115B2 (en) 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
KR20130122023A (ko) 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
US20080194529A1 (en) * 2007-02-12 2008-08-14 Auspex Pharmaceuticals, Inc. HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
NZ579169A (en) * 2007-02-12 2012-05-25 Dmi Biosciences Inc Treatment of comorbid premature ejaculation and erectile dysfunction using tramadol and a phosphodiesterase (pde) inhibitor
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
WO2009030095A1 (en) * 2007-09-06 2009-03-12 Topharman Shanghai Co., Ltd. Process for preparing vardenafil and its intermediates
WO2009082845A1 (en) 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)benzenesulfonyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
AU2010280358A1 (en) 2009-08-07 2012-03-08 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
ES2524826T3 (es) 2009-11-27 2014-12-12 Bayer Intellectual Property Gmbh Procedimiento para la purificación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
WO2011075801A1 (pt) 2009-12-21 2011-06-30 Acef S.A. Cubebina, lignana dibenzilbutirolactólica, seus derivados semi-sintéticos e sintéticos, bem como outras lignanas e neolignanas como agente vasodilatador na terapia da disfunção erétil
PL390079A1 (pl) * 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
RU2603140C2 (ru) 2010-09-20 2016-11-20 Айронвуд Фармасьютикалз, Инк. Соединения имидазотриазинона
MX2013003344A (es) 2010-09-23 2013-06-28 Abbvie Inc Monohidrato de un derivado de azaadamantano.
SI2637664T1 (sl) 2010-10-15 2017-07-31 Gilead Sciences, Inc. Sestavki in postopki zdravljenja pljučne hipertenzije
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
IN2015DN02829A (es) 2011-10-10 2015-09-11 Lundbeck & Co As H
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ2011767A3 (cs) 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
AU2013213603B2 (en) 2012-01-26 2017-02-02 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
WO2013129889A2 (ko) 2012-02-28 2013-09-06 주식회사 서울제약 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
US9750743B2 (en) 2012-12-04 2017-09-05 Aribio Inc. Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
AU2014220801A1 (en) 2013-02-21 2015-09-10 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
CN104109164B (zh) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
EP3022205B1 (en) 2013-07-17 2020-02-05 The Trustees of Columbia University in the City of New York Novel phosphodiesterase inhibitors and uses thereof
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
MX2018000283A (es) 2015-07-07 2018-11-22 H Lundbeck As Inhibidores de fde9 con estructura basica de imidazotriazinona y estructura basica de imidazopirazinona en el tratamiento de enfermedades perifericas.
CA3001728A1 (en) 2015-11-16 2017-05-26 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
WO2018215433A1 (en) 2017-05-22 2018-11-29 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN107445964A (zh) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 一种盐酸伐地那非杂质的合成方法
CN111655229A (zh) 2017-12-20 2020-09-11 卡里亚制药控股有限公司 包含伐地那非的薄膜制剂、其制备方法及其用途
US11348670B2 (en) 2018-06-14 2022-05-31 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
WO2019241588A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CN113166157A (zh) * 2018-11-28 2021-07-23 托帕杜制药公司 新型双作用模式可溶性鸟苷酸环化酶活化剂和磷酸二酯酶抑制剂及其用途
KR20210139317A (ko) 2019-03-13 2021-11-22 오츠카 세이야쿠 가부시키가이샤 2급 아민을 함유하는 화합물의 아민 부분에 중수소 저급 알킬을 도입하는 방법
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2022123310A1 (en) * 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
CN114085225A (zh) * 2021-06-04 2022-02-25 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
IL310526A (en) 2021-09-29 2024-03-01 Topadur Pharma Ag Topical compounds of 2-phenyl-4,3-dihydropyrrolo[2,F-L][4,2,1]triazinone derivatives and their uses
WO2023166013A1 (en) 2022-03-02 2023-09-07 Topadur Pharma Ag Topical compositions and uses therof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (de) 1944-12-07 1951-09-06 Georges Lissac Brille
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (es) 1963-01-16
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
EP0054132B1 (de) 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
WO1991015194A1 (en) * 1990-04-11 1991-10-17 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
WO1995007267A1 (fr) 1993-09-10 1995-03-16 Eisai Co., Ltd. Compose de quinazoline
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
KR20020062770A (ko) * 1999-12-24 2002-07-29 바이엘 악티엔게젤샤프트 이미다조 1,3,5 트리아지논 및 그의 용도
CA2449163C (en) 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHARLES, I. et al. Bicyclic Heterocycles with Nitrogen at the Ring Junction. Part 2. Application of the Dakin-West Reaction to the Synthesis of Imidazo-[5,1-f]-1,2,4-triazin-4(3H)-ones. Journal of the Chemical Society, Perkin Transactions 1, Nº 5, Mayo 1980, páginas 1139-1146. *

Also Published As

Publication number Publication date
TR200001338T2 (tr) 2000-08-21
AU738675B2 (en) 2001-09-20
FI113772B (fi) 2004-06-15
AU1558799A (en) 1999-05-31
HRP20000292B1 (en) 2008-09-30
UY25671A1 (es) 2000-03-31
CZ20001759A3 (cs) 2000-10-11
PT1049695E (pt) 2002-07-31
AR013759A1 (es) 2001-01-10
HUP0100394A2 (hu) 2001-09-28
DK1174431T3 (da) 2012-08-20
LU90561B1 (de) 2000-12-01
GB2346877B (en) 2001-12-05
EP1174431B1 (de) 2012-05-30
BR9812785A (pt) 2000-10-10
US7122540B2 (en) 2006-10-17
DE19881732C1 (de) 2002-01-31
ID25871A (id) 2000-11-09
UY25246A1 (es) 2001-08-27
EE200000291A (et) 2001-06-15
NO20021714L (no) 2000-05-11
UA46166C2 (uk) 2002-05-15
DK176852B1 (en) 2009-12-14
HU230154B1 (hu) 2015-09-28
ATE213246T1 (de) 2002-02-15
SK287161B6 (sk) 2010-02-08
US6566360B1 (en) 2003-05-20
TWI229081B (en) 2005-03-11
US20040067945A1 (en) 2004-04-08
SE0001745D0 (sv) 2000-05-11
US20130059844A1 (en) 2013-03-07
ES2386420T3 (es) 2012-08-20
BR9816155B1 (pt) 2010-07-27
US20110009367A1 (en) 2011-01-13
ES2172945T3 (es) 2002-10-01
NO20002444D0 (no) 2000-05-11
SE522809C2 (sv) 2004-03-09
HRP20020585B1 (hr) 2013-02-28
HN1998000175A (es) 1999-01-08
JP3356428B2 (ja) 2002-12-16
IL163475A (en) 2015-11-30
KR20040014591A (ko) 2004-02-14
NZ504436A (en) 2001-08-31
CO4980861A1 (es) 2000-11-27
US20100016323A1 (en) 2010-01-21
CA2395558A1 (en) 1999-05-20
SE0001745L (sv) 2000-05-11
US20080113972A1 (en) 2008-05-15
CA2395558C (en) 2007-07-17
US6362178B1 (en) 2002-03-26
DK1049695T3 (da) 2002-05-13
CA2309332A1 (en) 1999-05-20
PL201336B1 (pl) 2009-03-31
US7704999B2 (en) 2010-04-27
JP4388729B2 (ja) 2009-12-24
SI1174431T1 (sl) 2012-09-28
WO1999024433A1 (de) 1999-05-20
NO20021714D0 (no) 2002-04-11
KR20010031944A (ko) 2001-04-16
KR100548120B1 (ko) 2006-02-02
NO314940B1 (no) 2003-06-16
ES2194567A1 (es) 2003-11-16
EP1049695A1 (de) 2000-11-08
JP2001522851A (ja) 2001-11-20
HUP0100394A3 (en) 2002-05-28
CA2309332C (en) 2002-12-03
US7696206B2 (en) 2010-04-13
US20050070541A1 (en) 2005-03-31
MY138535A (en) 2009-06-30
FI20001086A (fi) 2000-05-09
KR100430355B1 (ko) 2004-05-04
CU23063A3 (es) 2005-07-19
US6890922B2 (en) 2005-05-10
CN100430396C (zh) 2008-11-05
BG65257B1 (bg) 2007-10-31
HU227841B1 (en) 2012-05-02
US20060189615A1 (en) 2006-08-24
IL135462A (en) 2006-04-10
SK7092000A3 (en) 2001-03-12
TW513431B (en) 2002-12-11
AR035972A2 (es) 2004-07-28
GB0010974D0 (en) 2000-06-28
EP1174431A3 (de) 2002-01-30
US7314871B2 (en) 2008-01-01
DE59803108D1 (de) 2002-03-21
BG104406A (en) 2001-08-31
DE19881732D2 (de) 2000-08-24
HRP20000292A2 (en) 2001-04-30
GB2346877A (en) 2000-08-23
JP2002348290A (ja) 2002-12-04
EE04781B1 (et) 2007-02-15
IL135462A0 (en) 2001-05-20
PT1174431E (pt) 2012-07-24
PL340400A1 (en) 2001-01-29
NO20002444L (no) 2000-05-11
HK1067124A1 (en) 2005-04-01
CY1112949T1 (el) 2016-04-13
EP1174431A2 (de) 2002-01-23
DK200000766A (da) 2000-05-09
HK1031730A1 (en) 2001-06-22
PE131799A1 (es) 1999-12-30
CN1123573C (zh) 2003-10-08
CZ301911B6 (cs) 2010-07-28
SI1049695T1 (en) 2002-06-30
EP2295436A1 (de) 2011-03-16
EP1049695B1 (de) 2002-02-13
HU228196B1 (en) 2013-01-28
CN1508137A (zh) 2004-06-30
HRP20020585A2 (en) 2005-10-31
PL194801B1 (pl) 2007-07-31
CH693954A5 (de) 2004-05-14
CN1278822A (zh) 2001-01-03
IN188419B (es) 2002-09-21

Similar Documents

Publication Publication Date Title
ES2194567B1 (es) Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas.
ES2183937T3 (es) Inhibidores de la adhesion celular.
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
ES2067466T5 (es) Dispersante.
GT200000198A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
PA8680701A1 (es) Derivados de oxindol
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
MX9703868A (es) Inhibidores de cgmp-pde para el tratamiento de disfuncion erectil.
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
GT199800128A (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados.
PA8446301A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas
ES2179945T3 (es) Compuestos de tetralina con actividad de resistencia a multiples farmacos.
CO4810381A1 (es) Combinacion eficaz para el tratamiento de la impotencia
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
GT200100251A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida
ES2174921T3 (es) Inhibidores de la proteasa del vih.
UY27413A1 (es) Agonistas de la oxitocina
ES2132419T3 (es) Nuevos agentes de nucleosidos 9-n-biciclicos utiles como inhibidores selectivos de citocinas proinflamatorias.
ES2061811T3 (es) Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera.
MX9302803A (es) Procedimiento para el normalizado y el estabilizado de poliisocianatos organicos.
ECSP024267A (es) Imidazotriazinonas sustituidas por 2-fenilo
AR037140A1 (es) Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende
ECSP066281A (es) Pirazolinas como antagonistas de par-1 para el tratamiento de enfermedades cardiocirculatorias
ECSP982739A (es) Imidazotriazinonas sustituidas por 2- fenilo

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031116

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2194567B1

Country of ref document: ES

PC2A Transfer of patent
PC2A Transfer of patent

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Effective date: 20130319

FD2A Announcement of lapse in spain

Effective date: 20190226